GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

LXRX · Dec 31, 2024

LEXICON PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001062822-25-000013General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

17.18% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-2979.17% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

3.85% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

89.73% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-3284.74% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1407.77% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

224.95% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History10 statesHistory building

Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/9 normalizedLevel 3 Mar 31, 20266/8 normalizedLevel 3 Jun 30, 20266/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 17.63%
Current: 17.18%
Delta: -0.45%

Cash Generation Increased

Previous: -3079.78%
Current: -2979.17%
Delta: 100.61%

Inventory Pressure Decreased

Previous: 36.53%
Current: 3.85%
Delta: -32.68%

Margin Decreased

Previous: 95.92%
Current: 89.73%
Delta: -6.19%

Profitability Increased

Previous: -3658.41%
Current: -3284.74%
Delta: 373.68%

R And D Intensity Decreased

Previous: 1480.76%
Current: 1407.77%
Delta: -72.99%

Sbc Intensity Increased

Previous: 160.83%
Current: 224.95%
Delta: 64.12%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · LXRX Fundamental State →Has State · LEXICON PHARMACEUTICALS, INC. →Transitioned To · LXRX Fundamental State →Transitioned To · LXRX CAPEX_INTENSITY_DECREASED →Transitioned To · LXRX CASH_GENERATION_INCREASED →Transitioned To · LXRX INVENTORY_PRESSURE_DECREASED →Transitioned To · LXRX MARGIN_DECREASED →Transitioned To · LXRX PROFITABILITY_INCREASED →Transitioned To · LXRX R_AND_D_INTENSITY_DECREASED →Transitioned To · LXRX SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.